Bolt Biotherapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Bolt Biotherapeutics Inc.
- Former names
- Bolt Therapeutics, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Redwood City
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BOLT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001641281
- EIN
- 47-2804636
Board of directors
-
Brian O'callaghan · DirectorSince 2023
-
Edgar Engleman · DirectorSince 2023
-
Frank D. Lee · DirectorSince 2023
-
Jakob Dupont · DirectorSince 2024
- Since 2023
-
Kathleen Laporte · DirectorSince 2023
-
Laura Berner · DirectorSince 2023
-
Mahendra Shah · DirectorSince 2023
-
Nicole Onetto · DirectorSince 2023
-
Randall C. Schatzman · Director · Chief Executive OfficerSince 2023
-
Richard A. Miller M.D. · DirectorSince 2023
-
William P. Quinn · Director · President, CEO and CFOSince 2024
Chief executives
William P. Quinn
· President, CEO and CFO
Dates unknown
Randall C. Schatzman
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
87.0%
-
93.9%
Board connections
5 of this board's directors also sit on 11 other boards.
- via James Healy
- via Frank D. Lee
- via James Healy
- via Richard A. Miller M.D.
- via James Healy
- via Frank D. Lee
- via Kathleen Laporte
- via Jakob Dupont
- via Kathleen Laporte
- via James Healy
- via James Healy
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $5,594
- 4 purchases by 2 insiders
- Sold, last 12 months
- $128,281
- 9 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 18, 2026 | Yonehiro Grant Officer (Chief Operating Officer) | Open-market sale | −6,850 | $3.24 | $22,169 |
| Sep 18, 2026 | William P. Quinn Director, Officer (President, CEO and CFO) | Open-market sale | −9,132 | $3.24 | $29,555 |
| Sep 18, 2026 | Nemec Sarah Officer (Senior VP, Finance and PAO) | Open-market sale | −4,077 | $3.24 | $13,195 |
| Sep 17, 2026 | Yonehiro Grant Officer (Chief Operating Officer) | Open-market sale | −4,909 | $3.32 | $16,290 |
| Sep 17, 2026 | William P. Quinn Director, Officer (President, CEO and CFO) | Open-market sale | −6,545 | $3.32 | $21,718 |
| Sep 17, 2026 | Nemec Sarah Officer (Senior VP, Finance and PAO) | Open-market sale | −2,922 | $3.32 | $9,696 |
| Sep 16, 2026 | Yonehiro Grant Officer (Chief Operating Officer) | Open-market sale | −1,417 | $3.77 | $5,348 |
| Sep 16, 2026 | William P. Quinn Director, Officer (President, CEO and CFO) | Open-market sale | −1,889 | $3.77 | $7,129 |
| Sep 16, 2026 | Nemec Sarah Officer (Senior VP, Finance and PAO) | Open-market sale | −843 | $3.77 | $3,181 |
| Jun 5, 2026 | William P. Quinn Director, Officer (President, CEO and CFO) | Open-market purchase | +637 | $3.88 | $2,469 |
| Jun 5, 2026 | Nemec Sarah Officer (Senior VP, Finance and PAO) | Open-market purchase | +509 | $3.88 | $1,973 |
| Dec 5, 2025 | William P. Quinn Director, Officer (President, CEO and CFO) | Open-market purchase | +125 | $4.61 | $576 |
| Dec 5, 2025 | Nemec Sarah Officer (Senior VP, Finance and PAO) | Open-market purchase | +125 | $4.61 | $576 |
| Oct 22, 2025 | Yonehiro Grant Officer (Chief Operating Officer) | Grant or award | +30,000 | — | — |
| Oct 22, 2025 | Nemec Sarah Officer (Senior VP, Finance and PAO) | Grant or award | +23,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.